Additionally, the 36-month beta value for TNFA is 2.07. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for TNFA is 13.48M and currently, short sellers hold a 20.61% ratio of that float. The average trading volume of TNFA on June 03, 2025 was 2.03M shares.
TNFA) stock’s latest price update
The stock price of TNF Pharmaceuticals Inc (NASDAQ: TNFA) has surged by 6.61 when compared to previous closing price of 0.16, but the company has seen a -1.95% decline in its stock price over the last five trading sessions. businesswire.com reported 2025-05-08 that BALTIMORE–(BUSINESS WIRE)—- $TNFA–TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health, a company committed to focusing on outpatient care to minimize costs, impact and the need for hospitalization, today announced positive results from the first stage of a general practice population study focusing on patients receiving GLP-1 agonists. The stu.
TNFA’s Market Performance
TNFA’s stock has fallen by -1.95% in the past week, with a monthly drop of -14.97% and a quarterly drop of -56.50%. The volatility ratio for the week is 4.74% while the volatility levels for the last 30 days are 8.06% for TNF Pharmaceuticals Inc The simple moving average for the past 20 days is -6.68% for TNFA’s stock, with a -82.35% simple moving average for the past 200 days.
TNFA Trading at -29.59% from the 50-Day Moving Average
After a stumble in the market that brought TNFA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.37% of loss for the given period.
Stock Fundamentals for TNFA
The total capital return value is set at -0.69. Equity return is now at value -121.95, with -88.26 for asset returns.
Based on TNF Pharmaceuticals Inc (TNFA), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -848.51.
Currently, EBITDA for the company is -23.36 million with net debt to EBITDA at 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.37.
Conclusion
In conclusion, TNF Pharmaceuticals Inc (TNFA) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
